Clinical Trial Update: A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial assessing safety, efficacy, and PK of delamanid in children with multidrug-resistant tuberculosis; completed with results posted in 2020…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis

Drugs mentioned

• Delamanid (delamanid)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Multidrug Resistant Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2020-11-23